Al Collinson, TheracosBio CEO

Ther­a­cos­Bio aims to chal­lenge Big Phar­ma block­busters with new­ly-ap­proved SGLT2 for di­a­betes

Ther­a­cos­Bio is squar­ing up for its lit­tle-en­gine-that-could mo­ment. Its type 2 di­a­betes med Bren­zavvy nabbed FDA ap­proval on Fri­day, land­ing the pri­vate­ly-fund­ed, lit­tle-known biotech in a big are­na al­ready pop­u­lat­ed by Big Phar­ma play­ers.

John­son & John­son’s In­vokana, As­traZeneca’s Farx­i­ga, and Boehringer In­gel­heim and Eli Lil­ly’s co-mar­ket­ed Jar­diance are long-es­tab­lished SGLT2 in­hibitors. In­vokana was first ap­proved in 2013, fol­lowed by Jar­diance and As­traZeneca in 2014, giv­ing them a head start of al­most a decade on Bren­zavvy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.